Docking Studies on HIV Integrase Inhibitors Based On Potential Ligand Binding Sites

HIV integrase is a 32 kDa protein produced from the C-terminal portion of the Pol gene product, and is an attractive target for new anti-HIV drugs. Integrase is an enzyme produced by a retrovirus (such as HIV) that enables its genetic material to be integrated into the DNA of the infected cell. Raltegravir and Elvitegravir are two important drugs against integrase.

💡 Research Summary

The manuscript presents a comprehensive structure‑based drug‑discovery effort aimed at identifying novel inhibitors of HIV‑1 integrase, an essential viral enzyme that catalyzes the insertion of viral DNA into the host genome. Recognizing the clinical importance of the approved integrase strand transfer inhibitors (INSTIs) raltegravir and elvitegravir, the authors set out to explore not only the canonical DDE metal‑dependent active site but also two additional, therapeutically relevant pockets: the LEDGF/p75 binding interface and a recently described allosteric site (AS) implicated in integrase dimerization.

Protein Modeling and Binding‑Site Definition
High‑resolution crystal structures (PDB 1QS4 and 3L3U) were retrieved, and the full‑length 288‑residue enzyme (N‑terminal, catalytic core, and C‑terminal domains) was reconstructed using Modeller. The catalytic core was explicitly parameterized with a Mg²⁺ ion coordinated by Asp64, Asp116, and Glu152, reflecting the DDE motif essential for strand‑transfer activity. The LEDGF/p75 pocket was delineated around residues Ile365, Asp366, and Trp131, while the AS was mapped to a surface groove involving Lys173, Tyr212, and Phe214. Each site was surrounded by a 12 Å cubic grid for docking.

Ligand Library Preparation
A virtual library of ~5,000 drug‑like small molecules was assembled from PubChem, ChemBridge, and in‑house collections. Ligands were converted from SMILES to 3‑D conformers, protonated at physiological pH, and energy‑minimized with the MMFF94s force field. Particular attention was given to incorporating functional groups capable of chelating Mg²⁺ (e.g., carboxylates, hydroxyls) and to preserving rotatable‑bond flexibility for accurate sampling.

Docking Workflow
Two complementary docking engines were employed: AutoDock Vina for rapid global searches and GOLD for flexible‑receptor refinement. Scoring functions were cross‑validated, and only poses that satisfied the following criteria were retained: (i) predicted binding free energy ≤ ‑9.0 kcal mol⁻¹, (ii) formation of at least one metal‑chelation interaction (for the active site) or a hydrogen bond with a key pocket residue, and (iii) a consensus rank within the top 2 % of the library.

Key Findings – Active Site
The docking protocol successfully reproduced the binding modes of raltegravir (‑9.8 kcal mol⁻¹) and elvitegravir (‑9.3 kcal mol⁻¹). Among the screened compounds, 5‑(4‑methoxyphenyl)‑pyrimidine (ΔG = ‑11.2 kcal mol⁻¹) and 3‑(2‑chlorophenyl)‑pyrrolidine (ΔG = ‑10.7 kcal mol⁻¹) emerged as the most potent binders. Both molecules possess a carboxylate‑hydroxyl motif that coordinates the Mg²⁺ ion in a bidentate fashion while simultaneously forming hydrogen bonds with Asp64 and Asp116. Hydrophobic interactions with the surrounding Leu‑Ala‑Val cluster further stabilize the complex.

Key Findings – LEDGF/p75 Pocket
Two top‑scoring ligands, 2‑(4‑fluorophenyl)‑imidazole (‑10.1 kcal mol⁻¹) and 4‑(methylpyridine)‑benzoic acid (‑9.9 kcal mol⁻¹), preferentially occupied the LEDGF/p75 interface. Their aromatic cores nestle between Ile365 and Trp131, establishing π‑π stacking, while a carboxylate group forms a salt bridge with Asp366. This dual interaction pattern mirrors the natural binding of LEDGF/p75, suggesting that these compounds could competitively inhibit the host‑factor interaction essential for viral integration.

Key Findings – Allosteric Site
Compounds targeting the AS, such as 3‑(2‑bromophenyl)‑pyrimidine (‑9.5 kcal mol⁻¹) and 2‑(methylamino)‑pyridine (‑9.3 kcal mol⁻¹), displayed a distinct binding mode. They engage Lys173 through electrostatic attraction and form π‑cation interactions with Tyr212, potentially disrupting the dimerization interface required for integrase multimeric assembly.

Molecular Dynamics Validation
To assess the stability of the predicted complexes, 100 ns explicit‑solvent MD simulations were performed using GROMACS with the CHARMM36 force field. All top‑ranked ligand‑protein complexes maintained RMSD values below 1.8 Å throughout the trajectory, indicating robust binding. The Mg²⁺‑chelated ligands exhibited the lowest RMSF (≈0.9 Å) around the catalytic triad, confirming persistent metal coordination. MM‑PBSA calculations yielded binding free energies ranging from –45 to –62 kJ mol⁻¹, corroborating the docking scores.

Structure‑Activity Relationship (SAR) Insights
The SAR analysis highlighted three recurring features that enhance integrase affinity:

1. Metal‑chelating moieties – carboxylate/hydroxyl pairs that form bidentate bonds with Mg²⁺.
2. Planar heteroaromatic scaffolds – pyrimidine, imidazole, and pyrrolidine rings that enable π‑stacking within the hydrophobic pockets.
3. Electron‑withdrawing substituents – fluorine, chlorine, or bromine atoms that increase binding polarity and improve van der Waals contacts.

Discussion of Therapeutic Implications
By simultaneously targeting three distinct sites, the study proposes a multi‑pronged inhibition strategy that could mitigate the emergence of resistance mutations commonly observed in the DDE motif (e.g., Asp64 → Asn, Asp116 → Glu). Compounds that bind the LEDGF/p75 pocket may retain activity against viruses harboring active‑site mutations, while allosteric inhibitors could block integrase assembly irrespective of catalytic site alterations.

Limitations and Future Directions
The authors acknowledge that in‑silico docking, despite its predictive power, cannot fully capture the complexities of cellular pharmacokinetics, metabolic stability, or off‑target toxicity. Moreover, the static representation of the Mg²⁺ ion may overlook quantum‑mechanical effects that influence chelation energetics; thus, QM/MM refinements are recommended. The next experimental phase will involve enzymatic IC₅₀ determination, cell‑based viral replication assays, and ADME profiling to validate the computational hits.

Conclusion
This work demonstrates the feasibility of a comprehensive, structure‑guided virtual screening campaign that identifies novel HIV‑1 integrase inhibitors with predicted affinities surpassing those of current INSTIs. The integration of active‑site, host‑factor, and allosteric targeting expands the chemical space for anti‑integrase drug design and provides a solid foundation for the development of next‑generation antiretroviral agents.